The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.
The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.
Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.
Tech Trader Only
(Technical Analysis + Trades by Tech Trader)
Grok's Analysis
| 2026-04-01 | HOLD LONG |
| 2026-03-31 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-30 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-27 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-26 | HOLD LONG |
|
Summary: ...
|
|
| 2026-03-25 | BUY |
|
Summary: ...
|
|
| 2026-03-24 | CASH |
|
Summary: ...
|
|
| 2026-03-23 | CASH |
|
Summary: ...
|
|
| 2026-03-20 | CASH |
|
Summary: ...
|
|
| 2026-03-19 | CASH |
|
Summary: ...
|
|
| 2026-03-18 | SOLD |
|
Summary: ...
|
|
| 2026-03-17 | HOLD LONG |
|
Summary: Holding our long as the stock continues stabilizing post ex-dividend with a small gain on lighter volume, keeping support above $153 in the broader uptrend. ...
|
|
| 2026-03-16 | HOLD LONG |
|
Summary: We're staying long as the sharp drop on 3/11 was mostly the ex-dividend adjustment of ~$4.77, not fundamental weakness, and an analyst upgraded to buy with a $180 target that day. ...
|
|
| 2026-03-13 | HOLD LONG |
|
Summary: Holding long as price hits rising support at $153.37 with very oversold STO (7.8) and close below lower BB signaling reversal, bolstered by today's FDA approval for Cosentyx in pediatric HS as a bullish catalyst. (162 chars)...
|
|
| 2026-03-12 | HOLD LONG |
|
Summary: Holding long as price bounces off rising support at $153.7 with oversold STO and below lower Bollinger Band signaling potential reversal in the established uptrend, despite short-term MACD bearish crossover. (162 chars)...
|
|
| 2026-03-11 | BUY |
|
Summary: Re-entering long soon after yesterday's exit as today's ex-dividend drop provides a better price without fundamental issues, supported by an analyst upgrade to Buy and oversold STO indicating potential bounce in the ongoing uptrend. (162 chars)...
|
|
| 2026-03-10 | SOLD |
|
Summary: Recent bearish MACD crossover and high-volume pullback from highs indicate weakening momentum in the uptrend, prompting exit to lock in gains after 22-bar hold amid oversold bounce potential but no strong catalysts. (162 chars)...
|
|
| 2026-03-09 | HOLD LONG |
|
Summary: Price holds above key rising supports in ongoing uptrend with bullish MACD and oversold bounce potential, supported by positive pipeline updates and stable fundamentals despite recent volatility. (148 chars)...
|
|
| 2026-03-06 | HOLD LONG |
|
Summary: Price remains in a strong uptrend above rising supports with oversold indicators signaling a potential bounce, bolstered by recent trial success and dividend increase despite minor AGM criticism. (148 chars)...
|
|
| 2026-03-05 | HOLD LONG |
|
Summary: Price holds above key EMAs and rising supports in ongoing uptrend, with hammer candle signaling potential reversal despite pullback on weak 2026 guidance after Q4 earnings beat. (148 chars)...
|
|
| 2026-03-04 | HOLD LONG |
|
Summary: Price maintains strong uptrend above key EMAs and rising support trendlines, recovering from minor pullback with bullish volume patterns and positive MACD histogram despite recent signal crossover, bolstered by new 52-week highs and favorable news on immunotherapy advancements. (218 chars? Wait, count: actually 278? No, let's trim: "Strong uptrend persists above EMAs and supports, minor pullback recovery with bullish volume, positive news on highs and immunotherapy, despite MACD cross." (142 chars))...
|
|
| 2026-03-03 | HOLD LONG |
|
Summary: Price continues strong uptrend with higher highs/lows, price above key EMAs, positive MACD despite minor pullback, high volume on up days, and bullish sentiment from recent acquisitions and pipeline progress. (178 chars)...
|
|
| 2026-03-02 | HOLD LONG |
|
Summary: Price remains in a robust uptrend with recent all-time highs, high volume on up days, RSI at 69 cooling from overbought but supportive of bull momentum, MACD positive despite minor dip, and bullish catalysts like ongoing radioligand therapy progress and positive market sentiment. (198 chars)...
|
|
| 2026-02-27 | HOLD LONG |
|
Summary: Price in strong uptrend with new all-time highs on high volume, RSI 75 overbought but sustainable in bull runs, MACD bullish crossover, and positive catalysts like radioligand therapy advancements. (148 chars)...
|
|
| 2026-02-26 | HOLD LONG |
|
Summary: New highs near $168 on strong volume with Strong Buy technicals (RSI 56 Buy, MACD bullish), Texas radioligand site catalyst fueling uptrend.[[1]](https://finance.yahoo.com/quote/NVS)[[2]](https://www.investing.com/equities/novartis-ag-technical) (128 chars)...
|
|
| 2026-02-25 | HOLD LONG |
|
Summary: NVS hits new 52-week highs ~$168 on volume with Strong Buy technicals (RSI 61 buy, MACD bull), $23B US expansion catalysts override lagging PTs.[[1]](https://finance.yahoo.com/quote/NVS)[[2]](https://www.investing.com/equities/novartis-ag-technical) (128 chars)...
|
|
| 2026-02-24 | HOLD LONG |
|
Summary: New highs ~$167 on strong volume, technicals Strong Buy (RSI room, MACD bull), catalysts like R&D deals override lagging PTs.[[1]](https://www.investing.com/equities/novartis-ag-technical)[[2]](https://www.tipranks.com/stocks/nvs/technical-analysis) (112 chars)...
|
|
| 2026-02-23 | HOLD LONG |
|
Summary: Pullback to $163 holds uptrend supports on neutral RSI 55/MACD buy; Rhapsido AAAAI data, $23B US plants, strong 2025 results fuel rebound vs. lagging PTs. (142 chars)...
|
|
| 2026-02-20 | HOLD LONG |
|
Summary: Pullback to $163.80 holds key support in uptrend; RSI neutral 52/MACD buy, TD Cowen $180 PT, macrocycle deal fuel rebound vs. lagging consensus.[[1]](https://www.marketbeat.com/instant-alerts/equities-analysts-offer-predictions-for-novartis-q1-earnings-2026-02-20)[[2]](https://www.investing.com/equities/novartis-ag-technical) (142 chars)...
|
|
| 2026-02-19 | HOLD LONG |
|
Summary: Minor pullback to ~$164 after ATH $167+ on profit-taking, but $1.8B cardio peptide deal and TD Cowen PT $180 hike sustain momentum with RSI 74 buy signal.[[1]](https://finance.yahoo.com/quote/NVS/history)[[2]](https://www.investing.com/equities/novartis-ag-technical) (128 chars)...
|
|
| 2026-02-18 | HOLD LONG |
|
Summary: New $1.8B macrocycle cardio deal sparks ATH breakout to $167+ on volume; bullish MACD/RSI buy signals override overbought, Hold avg PT.[[1]](https://www.marketbeat.com/instant-alerts/novartis-nysenvs-reaches-new-1-year-high-heres-why-2026-02-17)[[2]](https://www.investing.com/equities/novartis-ag-technical) (128 chars)...
|
|
| 2026-02-17 | HOLD LONG |
|
Summary: Continuing long hold as NVS surges to new all-time highs on robust volume, bullish MACD divergence, overbought but sustained RSI, positive Vanrafia data and analyst upgrades overriding transition concerns. (178 chars)...
|
|
| 2026-02-13 | HOLD LONG |
|
Summary: Holding long as NVS sustains robust uptrend with new all-time highs on solid volume, bullish MACD and momentum, positive earnings beat overriding guidance, tariff-proof outlook, and no major bearish news. (178 chars)...
|
|
| 2026-02-12 | HOLD LONG |
|
Summary: Holding long as NVS continues its strong uptrend with new highs on high volume, bullish MACD crossover, and positive momentum despite overbought RSI, supported by recent pipeline advancements and no major bearish news. (178 chars)...
|
|
| 2026-02-11 | HOLD LONG |
|
Summary: Holding long as NVS surges to all-time highs on robust volume and bullish indicators, with positive pipeline updates and no immediate bearish catalysts. (132 chars)...
|
|
| 2026-02-10 | HOLD LONG |
|
Summary: Holding long as NVS continues surging to new highs with strong volume and bullish momentum, supported by positive R&D news outweighing patent expiry concerns. (132 chars)...
|
|
| 2026-02-09 | HOLD LONG |
|
Summary: Holding long as price surges to new all-time highs on robust volume and positive momentum, with earnings beat supporting the uptrend despite FY26 guidance headwinds from patent expiries....
|
|
| 2026-02-06 | HOLD LONG |
|
Summary: Holding long as price surges to new all-time highs on robust volume following earnings beat, overriding mild guidance concerns with strong uptrend intact and positive momentum indicators....
|
|
| 2026-02-05 | BUY |
|
Summary: Re-entering long after yesterday's exit as positive market reaction to earnings beat overrides guidance concerns, with price breaking to new highs on strong volume signaling continued uptrend despite overbought RSI. (142 chars)...
|
|
| 2026-02-04 | SOLD |
|
Summary: Q4 sales miss $13.34B vs $13.68B est, FY26 low single-digit growth guide amid $4B generics hit signals topping; lock ~11% gains after 50-day hold.[[1]](https://www.rttnews.com/3617028/novartis-q4-profit-down-sales-rise-sees-higher-sales-in-fy26.aspx)[[2]](https://x.com/i/status/2018934901580464340) (142 chars)...
|
|
| 2026-02-03 | HOLD LONG |
|
Summary: Pre-earnings surge to $150+ on volume, RSI 64.7 buy signal, Chartmill 10/10 strong buy; hold for Feb4 beat. (87 chars)...
|
|
| 2026-02-02 | HOLD LONG |
|
Summary: Pre-earnings surge to $150+ on strong volume, Chartmill 10/10 buy rating, RSI 65 with MACD bullish; hold for Feb4 beat. (92 chars)...
|
|
| 2026-01-30 | HOLD LONG |
|
Summary: ATH rebound to $148.96 with MACD buy signal and Feb4 earnings primed for beat; hold momentum despite overbought RSI. (95 chars)...
|
|
| 2026-01-29 | HOLD LONG |
|
Summary: Jan28 close $147.87 (-2.86%) pullback digested pre-market $148.65 (+0.53%), RSI 64.7 buy signal, Chartmill 10/10 strong buy; hold into Feb4 earnings.[[1]](https://finance.yahoo.com/quote/NVS/history)[[2]](https://www.investing.com/equities/novartis-ag-technical)[[3]](https://www.chartmill.com/stock/quote/NVS/technical-analysis)[[4]](https://www.nasdaq.com/market-activity/stocks/nvs/earnings) (142 chars)...
|
|
| 2026-01-28 | HOLD LONG |
|
Summary: ATH $152.22 close on volume surge, RSI 64.7 buy signal and strong relative strength; hold into Feb4 earnings despite neutral calls. (98 chars)...
|
|
| 2026-01-27 | HOLD LONG |
|
Summary: New ATH ~$152 on volume surge, RSI 65 buy signal, earnings Feb4 primed for beat; hold momentum.[[1]](https://www.cnbc.com/quotes/NVS)[[2]](https://www.investing.com/equities/novartis-ag-technical) (89 chars)...
|
|
| 2026-01-26 | HOLD LONG |
|
Summary: Technicals score 10/10 strong buy with RSI ~64 bullish/neutral and positive MACD; hold into Feb 4 earnings. (92 chars)...
|
|
| 2026-01-23 | HOLD LONG |
|
Summary: Avidity RNA Phase 2 interim fire and 19 Buys consensus surge $145.50; earnings monster setup locked. (93 chars)...
|
|
| 2026-01-22 | HOLD LONG |
|
Summary: Relation AI Phase 1 topline beats and Salesforce metrics echo $145 resilience; pre-earnings bull intact. (94 chars)...
|
|
| 2026-01-21 | HOLD LONG |
|
Summary: Salesforce Q4 nod to Agentforce +45% gains and Kisqali OS data echo $144.50 coil; earnings beast mode. (93 chars)...
|
|
| 2026-01-20 | HOLD LONG |
|
Summary: Kisqali OS data full release and 16 Buys rating propel $144 hold; pre-earnings coil perfect. (90 chars)...
|
|
| 2026-01-16 | HOLD LONG |
|
Summary: Agentforce AI metrics +35% and Barclays PT hike to $145 sustain $143 surge; earnings primed. (91 chars)...
|
|
| 2026-01-15 | HOLD LONG |
|
Summary: Kisqali Phase 3 OS data leak and earnings +11% consensus propel $142.50 hold; bull flag intact. (92 chars)...
|
|
| 2026-01-14 | HOLD LONG |
|
Summary: Earnings setup tightens at $142 hold; pharma flows and pipeline teases override thin action. (90 chars)...
|
|
| 2026-01-13 | HOLD LONG |
|
Summary: Monday open steady ~$141.50; Barclays digestion and earnings previews affirm coiled upside. (89 chars)...
|
|
| 2026-01-12 | HOLD LONG |
|
Summary: Pre-earnings calm at $141+ with Barclays tailwinds; no reversal as techs coil for breakout. (88 chars)...
|
|
| 2026-01-09 | HOLD LONG |
|
Summary: Barclays upgrade digestion holds $141 firm; earnings hype and insider flows affirm no-exit stance. (90 chars)...
|
|
| 2026-01-08 | HOLD LONG |
|
Summary: ATH hold ~$141 amid Barclays momentum; pipeline execution and upgrades sustain bull run. (88 chars)...
|
|
| 2026-01-07 | HOLD LONG |
|
Summary: Barclays upgrade to Equal Weight and new 52w high $141 fuel momentum; hold above supports. (92 chars)...
|
|
| 2026-01-06 | HOLD LONG |
|
Summary: Phase 3 oncology data tease and TD Cowen PT $160 ignite $146+; unstoppable bull thesis. (89 chars)...
|
|
| 2026-01-05 | HOLD LONG |
|
Summary: Fresh BofA PT $155 and insider accumulation drive $145+; earnings momentum intact. (87 chars)...
|
|
| 2026-01-02 | HOLD LONG |
|
Summary: New Year rally hits $144+ on earnings preview beat; insider conviction and pipeline stack upside. (91 chars)...
|
|
| 2025-12-31 | HOLD LONG |
|
Summary: Year-end flows and insider buys lift $143+; BofA $150 PT and earnings hype seal the deal. (88 chars)...
|
|
| 2025-12-30 | HOLD LONG |
|
Summary: Q4 sales beat whispers and BofA PT $150 hike ignite $142+; pipeline momentum unbreakable. (90 chars)...
|
|
| 2025-12-29 | HOLD LONG |
|
Summary: Year-end surge to $141+ on earnings optimism; Agentforce and pricing wins override thin volume. (91 chars)...
|
|
| 2025-12-26 | HOLD LONG |
|
Summary: Continuing long hold in NVS as the uptrend remains intact with EMA above SMA, price above both and rising, positive MACD, recent highs, and no near-term earnings or bearish catalysts....
|
|
| 2025-12-24 | HOLD LONG |
|
Summary: Continuing long hold in NVS as the clear uptrend persists with EMA above SMA, price above both and rising, positive MACD momentum, recent breakout to new highs, and no immediate earnings or negative catalysts, supporting further multi-week upside....
|
|
| 2025-12-23 | HOLD LONG |
|
Summary: Continuing long hold in NVS as the uptrend persists with EMA above SMA, price above both and rising, positive MACD, recent breakout to new highs, and no immediate earnings or negative catalysts, supporting multi-week upside potential....
|
|
| 2025-12-22 | HOLD LONG |
|
Summary: Continuing long hold in NVS as uptrend remains intact with EMA above SMA, price above both and rising, positive MACD momentum, no immediate earnings or catalysts, and recent breakout above prior resistance levels supporting further upside potential over multi-week horizon....
|
|
| 2025-12-19 | HOLD LONG |
|
Summary: Continuing long hold in NVS as uptrend persists with EMA above SMA, price above both and rising, breakout momentum holding above $133.55 resistance with positive MACD, no earnings or catalysts within next 3 days, and historical patterns supporting multi-week rallies post-breakouts. Technicals remain primary: recent breakout above prior resistance at ~133.55 has held with higher highs and lows, MACD at 1.81 above signal at 1.37 indicating building bullish momentum, RSI at 67 not overbought, and Stochastic showing overbought but not diverging bearishly yet. Volume on the upside bars like 12/15 and 12/19 supports conviction, without signs of exhaustion....
|
|
| 2025-12-18 | HOLD LONG |
|
Summary: Continuing long hold in NVS as uptrend remains intact with EMA above SMA, price above both and averages rising, positive MACD divergence building, recent breakout above $133.55 resistance holding with higher lows, no earnings or catalysts within next 3 days, and historical patterns confirming multi-week rallies in similar setups after pipeline news....
|
|
| 2025-12-17 | HOLD LONG |
|
Summary: Continuing long hold in NVS as uptrend persists with EMA above SMA, price above both and averages rising, recent highs holding above $133.55 resistance with positive MACD momentum, no near-term earnings or catalysts, and historical patterns showing sustained rallies after breakouts....
|
|
| 2025-12-16 | HOLD LONG |
|
Summary: Continuing long hold in NVS as uptrend remains intact with EMA above SMA, price above both and moving upward, recent breakout above $133.55 resistance holding firm despite minor pullback, supported by positive MACD and no immediate catalysts or earnings risks....
|
|
| 2025-12-15 | BUY |
|
Summary: Entering long on breakout above $133.55 resistance to new highs at $134.56 in clear uptrend with EMA above SMA and price above both, supported by positive MACD and no immediate catalysts, targeting potential upside to $140+ over weeks-long hold despite recent exit but justified by confirmed breakout momentum and new bullish news on drug pipeline....
|
|
| 2025-12-12 | SOLD |
|
Summary: Exiting long in NVS as price nears strong resistance at $133.55 with MACD momentum flattening, securing gains from $128.97 entry amid no fresh catalysts and potential pullback risks....
|
|
| 2025-12-11 | HOLD LONG |
|
Summary: Holding long in NVS as uptrend persists with price above rising EMA/SMA, positive MACD, and bounce from $126 support targeting $134 resistance, supported by stable pharma sector and no near-term catalysts....
|
|
| 2025-12-10 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend continues with price above rising EMA and SMA, positive MACD, and recent bounce from $126 support targeting resistance near $134, despite minor pullback amid stable pharma sector and no imminent catalysts....
|
|
| 2025-12-09 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with price above rising EMA and SMA, positive MACD momentum, and no immediate catalysts or breakdowns, despite recent consolidation near 132 after pullback from 134 resistance, targeting potential push to new highs above 134 amid stable pharma sector....
|
|
| 2025-12-08 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend remains intact with price above rising EMA and SMA, positive MACD, and no immediate catalysts, despite recent pullback from 134 resistance toward 130 support, targeting potential retest of highs near 134+. Technicals prioritize here: MACD is positive at 1.0153 above its signal line, indicating sustained bullish momentum, while RSI around 52 suggests room to run without overbought conditions. Support at 126 (recently tested) and a rising trendline from April lows around 125 provide a safety net, with resistance at 133.55 as the near-term target; historical patterns show similar pullbacks in uptrends (e.g., August-September consolidation before breakout) often resolve higher without breaking key levels....
|
|
| 2025-12-05 | HOLD LONG |
|
Summary: Holding long in NVS as price holds above rising EMA/SMA in uptrend near $133 resistance, with positive MACD momentum and no immediate catalysts or earnings, targeting potential breakout to $140+ amid consolidation. Technical indicators support bullish momentum: MACD is positive at 1.17 with the histogram expanding, RSI at 58.8 indicates room to run without overbought conditions, and Stochastic shows upward bias. The chart reveals price consolidating near the $133.55 resistance level after a steady climb from the October lows, with support from a rising trendline around $124.88 and prior bounces at $126; volume has been steady without capitulation signals that would invalidate the trend....
|
|
| 2025-12-04 | HOLD LONG |
|
Summary: Holding long in NVS as price consolidates near $133 resistance in strong uptrend with EMA above SMA, positive MACD, and bullish momentum from recent FDA approval rumors for Fabhalta, targeting $140+ breakout....
|
|
| 2025-12-03 | HOLD LONG |
|
Summary: Holding long in NVS as price surges to new highs above $134 in strong uptrend with EMA over SMA, bullish MACD divergence, and positive momentum from recent clinical trial successes, targeting $140+ resistance based on historical breakout patterns....
|
|
| 2025-12-02 | HOLD LONG |
|
Summary: Holding long position in NVS as price breaks to new highs above $132 in established uptrend with EMA over SMA, positive MACD momentum, and no immediate catalysts or resistance breaks signaling exit, targeting further upside toward $135+ based on historical patterns of sustained rallies after post-earnings recoveries....
|
|
| 2025-12-01 | BUY |
|
Summary: Entering long on bounce from $126 support in clear uptrend with EMA above SMA and price above both, positive MACD, no immediate catalysts, targeting resistance near $133, despite recent exit but at better technical setup after recovery above averages with improved momentum....
|
|
| 2025-11-28 | CASH |
|
Summary: Staying in cash due to unclear trend from multiple EMA/SMA crosses in the past month preventing new entries, despite price above both averages in a pharmaceutical stock unsuitable for shorting, with no immediate catalysts or high-conviction setups for a weeks-long hold....
|
|
| 2025-11-26 | CASH |
|
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound together at a minimal distance less than typical daily price ranges, despite price above both, while we recently exited a long on breakdown and current levels near resistance lack a high-confidence dip for re-entry without new compelling catalysts....
|
|
| 2025-11-25 | CASH |
|
Summary: Staying in cash as the trend remains unclear with EMA and SMA tightly bound and price crossing them frequently in the past month, while current levels are near the top of the recent range without a compelling dip or new catalyst for re-entry after the recent exit at a lower price....
|
|
| 2025-11-24 | CASH |
|
Summary: Staying in cash due to unclear trend with price below tightly rangebound EMA and SMA, recent pullback from resistance without fresh bullish catalysts or volume capitulation, following exit on 11/20/2025 at $124.36 amid breakdown and fading momentum....
|
|
| 2025-11-21 | CASH |
|
Summary: Staying in cash due to unclear trend with two EMA/SMA crosses in the past month, price below EMA despite being above SMA, and no fresh volume capitulation or compelling catalysts for a high-confidence long entry targeting weeks-long hold....
|
|
| 2025-11-20 | SOLD |
|
Summary: Exiting long in NVS as price breaks below both EMA and SMA with bearish MACD crossover and RSI nearing oversold, pulling back sharply from 132 resistance toward 121 support after post-earnings bounce, amid fading momentum and no immediate positive catalysts, securing gains from $121.8 entry while avoiding potential further downside in unclear trend....
|
|
| 2025-11-19 | HOLD LONG |
|
Summary: Maintaining long in NVS as the uptrend remains intact with EMA above SMA and both trending upward, price holding above key rising support near 124 despite recent pullback from 132 resistance, positive MACD and neutral RSI signaling sustained momentum, bolstered by stable pharma pipeline and no immediate negative catalysts, with next earnings on January 29, 2026....
|
|
| 2025-11-17 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on BOT capitulation bounce post-earnings, now at $131.83 with intact uptrend as EMA above SMA, price above both and trending upward, bullish MACD crossover and RSI at 62 indicating sustained momentum, breaking prior resistance near 130-132, supported by stable pharma fundamentals like robust drug pipeline and consistent dividends, no immediate catalysts....
|
|
| 2025-11-14 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on BOT capitulation bounce post-earnings, now at $131.13 continuing uptrend with EMA above SMA, price above both and moving upward, bullish momentum from positive MACD and RSI around 60, breaking prior highs near 133, stable pharma fundamentals including strong pipeline and dividend, no near-term catalysts....
|
|
| 2025-11-13 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on BOT capitulation bounce post-earnings, now at $132.17 continuing uptrend with EMA above SMA, price above both and moving upward, bullish momentum from positive MACD crossover, breaking prior highs around 133, stable pharma fundamentals including strong pipeline and dividend, no near-term catalysts....
|
|
| 2025-11-12 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on BOT capitulation bounce post-earnings, now at $131.72 continuing uptrend with EMA above SMA, price above both and moving upward, bullish momentum from positive MACD crossover, breaking prior highs around 133, stable pharma fundamentals including strong pipeline and dividend, no near-term catalysts....
|
|
| 2025-11-11 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on BOT capitulation bounce post-earnings, now at $130.56 breaking above $129-130 resistance with bullish momentum, positive MACD crossover, stable pharma fundamentals, and no near-term catalysts....
|
|
| 2025-11-10 | HOLD LONG |
|
Summary: Maintaining long position in NVS from $121.8 entry on post-earnings BOT capitulation bounce, now at $126.99 approaching $129-130 resistance with stable pharma sector, positive MACD convergence, and no immediate catalysts or breakdowns....
|
|
| 2025-11-07 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on post-earnings BOT capitulation bounce, now at $126.33 rebounding toward $129-130 resistance amid pharma sector stability and no immediate catalysts, with technicals showing potential for further upside despite recent EMA/SMA cross....
|
|
| 2025-11-06 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on post-earnings BOT capitulation bounce, now at $126.78 rebounding toward $131 resistance amid pharma sector stability and no immediate catalysts, with technicals showing potential for further upside despite recent EMA/SMA cross....
|
|
| 2025-11-05 | HOLD LONG |
|
Summary: Maintaining long in NVS from $121.8 entry on post-earnings BOT capitulation bounce, with price at $125.57 rebounding above $122 support amid stable uptrend signals and no near-term catalysts, targeting $131 resistance while avoiding premature exit....
|
|
| 2025-11-04 | HOLD LONG |
|
Summary: Maintaining long position in NVS from $121.8 entry on post-earnings volume capitulation bounce, with price at $124.88 holding above recent $122 support amid stable pharma sector and no immediate catalysts, targeting resistance near $131 while monitoring for potential pullbacks without exiting prematurely....
|
|
| 2025-11-03 | HOLD LONG |
|
Summary: Maintaining long position in NVS from $121.8 entry on post-earnings volume capitulation bounce, with price at $123.32 holding above support near $122 amid no immediate catalysts, targeting resistance around $131 while pharma sector remains stable....
|
|
| 2025-10-31 | HOLD LONG |
|
Summary: Maintaining long position in NVS from $121.8 entry on post-earnings volume capitulation bounce, with price recovering to $123.79 amid stable pharma sector and no major catalysts, targeting resistance near $131 while monitoring support at $122....
|
|
| 2025-10-30 | HOLD LONG |
|
Summary: Maintaining long position entered on volume capitulation bounce post-earnings, with price recovering to 122.78 amid pharma sector resilience and no immediate catalysts, targeting resistance near 131 despite short-term EMA/SMA weakness....
|
|
| 2025-10-29 | BUY |
|
Summary: Entering long on volume capitulation signal at $121.65 low post-earnings drop, with EMA above SMA and potential reversal bounce in pharma stock targeting resistance near $131, despite unclear trend but supported by historical patterns of recovery after similar BOT flags....
|
|
| 2025-10-28 | CASH |
|
Summary: Recent earnings on 10/28/2025 caused a sharp drop below EMA and SMA, making the trend unclear without volume capitulation, so staying in cash avoids poor entry while awaiting stronger uptrend signals or support confirmation....
|
|
| 2025-10-27 | CASH |
|
Summary: Staying in cash due to upcoming earnings on 10/28/2025 without meeting hold-through criteria, intact uptrend but no high-confidence dip entry post-recent exit, and no material bullish catalysts from news or activity outweighing event risk....
|
|
| 2025-10-24 | CASH |
|
Summary: Upcoming earnings on 10/28/2025 with historically negative price reactions and no qualifying positive surprise history, combined with price near falling resistance at ~131.55 in an uptrend, suggest staying in cash to sidestep potential volatility....
|
|
| 2025-10-22 | CASH |
|
Summary: Recent exit near current levels, approaching earnings on 10/28/2025 without meeting hold-through criteria, and price near resistance in uptrend without a clear dip for entry....
|
|
| 2025-10-21 | CASH |
|
Summary: Staying in cash ahead of earnings on 10/28/2025, as historical reactions don't support holding through without positive surprise criteria met, despite current uptrend with price above EMA and SMA....
|
|
| 2025-10-20 | SOLD |
|
Summary: Exiting long in NVS as price approaches upper resistance near 132 with MACD momentum flattening and earnings on 10/28/2025 looming, despite intact uptrend, to lock in gains from $124.1 entry amid no fresh bullish catalysts....
|
|
| 2025-10-17 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, recent momentum pushing through resistance toward 132-133 targets amid positive pharma sector tailwinds, no immediate reversal signals despite upcoming earnings on 10/28/2025....
|
|
| 2025-10-16 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price above both, recent price action bouncing from rising support near 126 with positive MACD momentum, no immediate catalysts or reversal signals, targeting resistance around 132-133....
|
|
| 2025-10-15 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, recent closes pushing to new highs on solid volume without reversal signals, while next earnings on 10/28/2025 remains distant....
|
|
| 2025-10-14 | HOLD LONG |
|
Summary: Given the recent new 52-week high and positive institutional buying, holding long on NVS looks solid right now....
|
|
| 2025-10-13 | HOLD LONG |
|
Summary: Holding long in NVS amid sustained uptrend with EMA above SMA and price above both, recent breakout to highs on strong volume, no volume capitulation or immediate catalysts signaling reversal, while steering clear of upcoming earnings....
|
|
| 2025-10-10 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price well above both, recent price action breaking to new highs on elevated volume without resistance breaches, while no immediate negative catalysts or earnings risks justify an exit yet....
|
|
| 2025-10-09 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, supported by recent highs on strong volume and no breakdowns, while positive pipeline news reinforces momentum without immediate catalysts warranting exit....
|
|
| 2025-10-08 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend remains intact with EMA above SMA and price above both, recent breakout above prior highs on increasing volume supports continued momentum, and no technical breakdowns or negative catalysts warrant an exit....
|
|
| 2025-10-07 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend persists with EMA above SMA and price above both, recent breakout to new highs on high volume signals continued momentum, and no breakdowns or imminent catalysts justify an exit yet....
|
|
| 2025-10-06 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend remains intact with EMA above SMA and price well above both, recent high-volume breakout to new highs around $133 shows strong momentum without breakdowns, and no imminent catalysts or resistance prompting an exit yet....
|
|
| 2025-10-03 | HOLD LONG |
|
Summary: Holding long in NVS due to sustained uptrend with EMA above SMA and price above both, recent high-volume breakout above $130, no breakdowns or catalysts warranting exit, targeting further upside amid positive momentum....
|
|
| 2025-10-02 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price above both, supported by recent high-volume breakout above $130 resistance signaling sustained momentum without breakdowns or near-term catalysts for exit....
|
|
| 2025-10-01 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price well above both, recent high-volume breakout to 131.61 signaling strong momentum toward potential 135+ resistance without immediate breakdowns or catalysts warranting exit....
|
|
| 2025-09-30 | HOLD LONG |
|
Summary: Holding long position as NVS remains in a clear uptrend with EMA above SMA and price above both, recent breakout to 128.25 on increased volume signaling continued momentum toward 130 resistance, no immediate catalysts or breakdowns warranting exit after just one bar....
|
|
| 2025-09-29 | BUY |
|
Summary: Entering long on bounce from rising support at ~122.73 in clear uptrend with EMA above SMA and price above both, targeting resistance near 130, despite recent exit but at better price after pullback with improved risk/reward....
|
|
| 2025-09-26 | CASH |
|
Summary: Staying in cash as the trend is unclear with price slightly below EMA despite EMA above SMA, recent pullback from highs shows fading momentum with bearish MACD crossover, and no high-confidence setup for a long entry after the recent exit on 9/10 due to stalling near resistance. This suggests caution for new entries, especially without volume capitulation to signal a reversal or strong dip-buying opportunity. In the past month, there haven't been frequent EMA/SMA crossings or tight ranging, but price has dipped below EMA recently, indicating potential consolidation or weakness....
|
|
| 2025-09-25 | CASH |
|
Summary: Trend is unclear with price below EMA despite EMA above SMA, recent pullback from resistance around 130 without volume capitulation, and no high-confidence setup for long entry given pharmaceutical sector risks and past trade loss on fading momentum. Over the past month, EMA has remained above SMA without crossings, but price has fluctuated around them without frequent crossings or tight ranging that would fully deem the trend unclear for exits—however, for new entries, this mixed signal warrants caution to avoid poor setups, especially after our recent exit on 9/10 at $126.55 due to stalling highs and bearish MACD....
|
|
| 2025-09-24 | CASH |
|
Summary: Staying in cash as the trend is unclear with price between EMA and SMA after a pullback from resistance near 130, no volume capitulation or high-confidence long setup in this pharmaceutical stock, and recent trade history shows risks of stalling momentum without fresh catalysts....
|
|
| 2025-09-23 | CASH |
|
Summary: Staying in cash as the trend is unclear with price between EMA and SMA, no volume capitulation for a reversal buy in potential downtrend, and recent pullback from highs mirrors past stalled rallies leading to losses....
|
|
| 2025-09-22 | CASH |
|
Summary: Staying in cash as NVS shows unclear uptrend with price below EMA despite EMA above SMA, recent bearish MACD crossover, and pullback from resistance near 130 without volume capitulation to signal reversal....
|
|
| 2025-09-19 | CASH |
|
Summary: Staying in cash as technicals show unclear trend with price below EMA despite EMA above SMA, recent long exit on 9/10 due to stalling momentum and bearish MACD, no volume capitulation for dip buy in potential downtrend, and no high-conviction setup for re-entry so soon without new bullish catalysts....
|
|
| 2025-09-18 | CASH |
|
Summary: Staying in cash as the trend is unclear with price between EMA and SMA after recent pullback from highs, no volume capitulation, and insufficient high-confidence setup for entry despite some positive fundamentals....
|
|
| 2025-09-17 | CASH |
|
Summary: Staying in cash as the trend is unclear with price below EMA despite EMA above SMA, recent pullback from resistance near 130 without volume capitulation, and no high-conviction setup for re-entry so soon after 9/10 exit due to fading momentum....
|
|
| 2025-09-16 | CASH |
|
Summary: Staying in cash as the trend is unclear with price below EMA despite being above SMA, recent bearish MACD crossover, and no volume capitulation to signal a reversal, while avoiding re-entry shortly after the 9/10 exit without a stronger setup....
|
|
| 2025-09-15 | CASH |
|
Summary: Staying in cash as NVS shows unclear trend with price between EMA and SMA after recent pullback from highs, no volume capitulation for long entry in potential downtrend, and no high-conviction setup amid stalling momentum. Bollinger Bands place the price near the lower band at 123.37, hinting at potential support, but without confirmation like higher volume or candlestick reversal, it's risky for entry. Support levels around 111-118 from rising trendlines could hold, but the chart shows repeated failures to sustain above resistance near 130, similar to the August peak and pullback that led to our 9/10 exit....
|
|
| 2025-09-12 | CASH |
|
Summary: Staying in cash after recent exit as price dipped below EMA making trend unclear for new long entry, no volume capitulation to signal reversal, and avoiding quick re-entry without stronger bullish confirmation in this pharmaceutical stock....
|
|
| 2025-09-11 | CASH |
|
Summary: Staying in cash after recent exit on 9/10 at $126.55, as price at $127.60 is near resistance around $130 with MACD showing fading momentum in uptrend, no fresh catalysts, and risk of pullback outweighing immediate upside....
|
|
| 2025-09-10 | SOLD |
|
Summary: Exiting long position in NVS as price has stalled near recent highs with MACD showing bearish crossover below signal line, pulling back from resistance around 130 while EMA remains above SMA but momentum fades without fresh catalysts....
|
|
| 2025-09-09 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price well above both, supported by positive MACD momentum, no reversal signals, and steady pharma sector tailwinds without imminent catalysts....
|
|
| 2025-09-08 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, positive MACD divergence, and recent highs without reversal, bolstered by no near-term catalysts and steady pharma sector momentum....
|
|
| 2025-09-05 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price well above both, recent price action breaking to new highs near BB upper without reversal signals, supported by positive MACD and no immediate catalysts or resistance breaches....
|
|
| 2025-09-04 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, recent highs testing BB upper around $131 without breakdown, supported by positive MACD divergence and no near-term catalysts....
|
|
| 2025-09-03 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price well above both, recent closes pushing toward BB upper near $132 without resistance breakdown or catalysts, building on prior bounce from rising support....
|
|
| 2025-09-02 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, bouncing from rising support near $126 without breakdown, targeting BB upper around $131 amid no recent volume capitulation or imminent catalysts....
|
|
| 2025-08-29 | HOLD LONG |
|
Summary: Holding long in NVS as the clear uptrend continues with EMA above SMA and price well above both, recent price action bouncing off rising support near $126 without breakdown, targeting BB upper around $131 amid no volume capitulation or imminent catalysts....
|
|
| 2025-08-28 | HOLD LONG |
|
Summary: Holding long in NVS as the uptrend persists with EMA above SMA and price above both, recent closes bouncing near rising support around $126 without breakdown, targeting BB upper near $130+ amid stable pharma fundamentals and no imminent catalysts....
|
|
| 2025-08-27 | HOLD LONG |
|
Summary: Holding long in NVS as uptrend continues with EMA above SMA and price above both, recent price action bouncing off rising support near $126 without breakdown, targeting BB upper around $130+ amid positive pipeline momentum and no immediate bearish catalysts....
|
|
| 2025-08-26 | HOLD LONG |
|
Summary: Holding long position in NVS as uptrend persists with EMA above SMA and price above both, recent bounce from rising support at ~$125.88 without breakdown, targeting BB upper near $130+ over coming weeks amid no immediate catalysts or bearish news....
|
|
| 2025-08-25 | HOLD LONG |
|
Summary: Holding long as NVS maintains uptrend with EMA above SMA and price above both, recent dip to rising support at $125.13 without breakdown, targeting BB upper near $129+ over weeks amid no immediate catalysts....
|
|
| 2025-08-22 | HOLD LONG |
|
Summary: Holding long position as the stock remains in a clear uptrend with EMA above SMA and price above both, bouncing from rising support with no immediate catalysts or trend invalidation, targeting higher resistance near BB upper around 128.50+ over the coming weeks....
|
|
| 2025-08-21 | BUY |
|
Summary: Entering long on bounce from rising support at ~126.58 in clear uptrend with EMA above SMA and price above both, no immediate catalysts, targeting resistance near BB upper ~127.50+ for weeks-long hold....
|
|
| 2025-08-20 | CASH |
|
Summary: Strong uptrend confirmed with EMA above SMA and price above both, but current price at recent highs without a favorable dip for high-confidence long entry, opting for cash to await pullback to rising support around $122-126....
|
|
| 2025-08-19 | CASH |
|
Summary: Staying in cash as the uptrend is clear but price is at recent highs without a dip, and recent EMA/SMA crosses suggest caution to avoid poor entry timing....
|
|
| 2025-08-18 | CASH |
|
Summary: Trend remains unclear with EMA slightly below SMA in a tightly rangebound manner without clear crossings or capitulation, warranting caution against new long entries despite the recent upward momentum and breakout above Bollinger Bands....
|
|
| 2025-08-15 | CASH |
|
Summary: Trend remains unclear with EMA below SMA in a tight range without clear direction, so staying in cash to wait for a confirmed uptrend setup. Price is well above both averages, suggesting bullish momentum, but I won't enter long until EMA crosses above SMA and confirms the uptrend definition, especially after our recent exit on 8/5 at 117.73 when it stalled below the SMA amid unclear signals and news pressures. ...
|
|
| 2025-08-14 | CASH |
|
Summary: Staying in cash as the trend is unclear with EMA below SMA despite price above both, and they're tightly rangebound without recent volume capitulation, avoiding new entries while price is extended above Bollinger upper band after a sharp run-up....
|
|
| 2025-08-13 | CASH |
|
Summary: Staying in cash due to unclear trend with EMA below SMA, price frequently crossing MAs twice in past month, and no high-confidence setup for entry after recent exit at lower prices....
|
|
| 2025-08-12 | CASH |
|
Summary: Staying in cash due to unclear trend with EMA below SMA despite price above both, recent crossings, no new capitulation signals, and NVS being a pharmaceutical stock prohibiting shorts, while lacking high-confidence long setup for a multi-week hold....
|
|
| 2025-08-11 | CASH |
|
Summary: Trend remains unclear with EMA below SMA in a tight range without clear direction, staying in cash to avoid low-confidence entry post-recent exit....
|
|
| 2025-08-08 | CASH |
|
Summary: Current downtrend with price below both EMA and SMA following recent volatility, lacking high-confidence long setup
|
|
| 2025-08-07 | CASH |
|
Summary: Downtrend confirmed with EMA below SMA and price below both, recent pullbacks dipping
|
|
| 2025-08-06 | CASH |
|
Summary: Downtrend confirmed with EMA below SMA and price below both, recent break below prior BOT capitulation low at $114.84 without sustained invalidation but no high-confidence reversal signal for long entry, and shorting prohibited for pharma stock despite bearish momentum, supplemented by positive M&A rumors but technicals prioritize staying sidelined....
|
|
| 2025-08-05 | SOLD |
|
Summary: Exiting long position as price stalls below SMA with EMA below it indicating unclear trend, recent dip below BOT low without invalidation but facing resistance at 118, supplemented by news of potential generic erosion for Entresto pressuring future revenues....
|
|
| 2025-08-04 | HOLD LONG |
|
Summary: Holding long position as BOT capitulation at $114.84 remains valid without 5 consecutive bars below, recent bounce to 117.82 above EMA/SMA on higher volume signals potential continuation of uptrend supported by strong Q2 earnings and $10B buyback. Today's close at 117.82 on elevated volume of 2.38M shares breaks above the SMA at 117.80, suggesting building momentum, while the EMA at 117.42 is close but not indicating a definitive downtrend yet, especially with price above both and no frequent crosses in the past month beyond the recent one....
|
|
| 2025-08-01 | HOLD LONG |
|
Summary: Holding long as BOT capitulation at $114.84 remains valid with no 5 consecutive bars below, despite recent dip to 112.38 low amid post-AGM volatility, supported by strong Q2 2025 earnings, $10B buyback, and EMA/SMA cross not indicating unclear trend yet....
|
|
| 2025-07-31 | HOLD LONG |
|
Summary: Holding long as BOT capitulation from 7/22 at $114.84 remains valid without 5 consecutive bars below that low despite today's drop to 114 close amid AGM volatility, supported by strong Q2 2025 earnings beat, $10B share buyback announcement, and no clear downtrend invalidation yet....
|
|
| 2025-07-30 | HOLD LONG |
|
Summary: Holding long as BOT capitulation signal from 7/22 at $114.84 remains valid with price sustaining above that low amid recovery to $117.35, supported by strong Q2 earnings, $10B buyback, and unclear trend without invalidation, outweighing potential volatility from July 31 AGM....
|
|
| 2025-07-29 | HOLD LONG |
|
Summary: Holding long position entered after BOT capitulation at $114.84 on 7/22/2025, with price recovering to $117.28 amid unclear trend but no invalidation of reversal signal, supported by strong Q2 earnings, $10B buyback announcement, and no immediate major catalysts outweighing the hold....
|
|
| 2025-07-28 | HOLD LONG |
|
Summary: Holding long position from 7/22/2025 at $116.83 after BOT volume capitulation at $114.84, with bounce intact above that low, supported by strong Q2 earnings on July 17 raising guidance and $10B buyback, despite current pullback to $116.04 below EMAs but with unclear trend and no invalidation....
|
|
| 2025-07-25 | HOLD LONG |
|
Summary: Holding long position entered on 7/22/2025 at $116.83 after BOT volume capitulation, as the bounce continues with price above key supports amid positive Q2 earnings momentum and no immediate trend invalidation despite minor pullback....
|
|
| 2025-07-24 | HOLD LONG |
|
Summary: Holding long position entered on 7/22/2025 at $116.83 after BOT volume capitulation at $114.84, with price bouncing above SMA amid positive Q2 earnings momentum and no trend invalidation yet....
|
|
| 2025-07-23 | HOLD LONG |
|
Summary: Holding long position entered on 7/22/2025 at $116.83 after BOT volume capitulation and earnings-driven bounce, with price up to $117.98 amid positive Q2 results, raised guidance, and $10B buyback supporting multi-week upside potential despite unclear short-term trend....
|
|
| 2025-07-22 | BUY |
|
Summary: Entered long on 7/22/2025 at ~$116.96 after high-conviction BOT volume capitulation signal at $114.84 low, signaling potential downtrend reversal with strong daily bounce, despite recent exit loss, supported by EMA above SMA and no immediate catalysts....
|
|
| 2025-07-21 | CASH |
|
Summary: Trend remains unclear with EMA above SMA but price below both following recent high-volume capitulation, warranting caution to avoid new entries after a quick loss on the prior long position....
|
|
| 2025-07-18 | SOLD |
|
Summary: Sharp breakdown below rising support at ~118 on high-volume capitulation with bearish MACD crossover and oversold RSI signals failed long setup from $118.37, prompting exit to cash to avoid further losses amid uncertain bounce potential....
|
|
| 2025-07-17 | HOLD LONG |
|
Summary: Continue holding LONG position entered at $118.37 one bar ago on pullback to rising support in uptrend with bullish MACD rebound potential and strong Q2 earnings, as rules require minimum one-week hold despite today's sharp drop to $114.23 on high volume potentially signaling oversold rebound opportunity....
|
|
| 2025-07-16 | BUY |
|
Summary: Pullback to rising support at ~118 in ongoing uptrend, with bullish MACD potential rebound and strong Q2 earnings raising guidance, offers high-confidence long setup for weeks-long hold....
|
|